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Abstract
Background: Vascularization is an exciting and complex mechanism involving angiogenesis and
arteriogenesis. The metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) are associated
with multiple metabolic toxicities, which result in reactive oxygen species (ROS) due to an elevated
tension of oxidative-redox stress and an accelerated atherosclerosis termed atheroscleropathy.
Results: This atheroscleropathy is associated with accelerated angiogenesis within the vulnerable,
thin-cap fibro-atheroma, prone to rupture resulting in acute coronary syndromes (ACS). The
resulting intimopathy with its neovascularization due to angiogenesis of the adventitial vasa
vasorum (Vv) is prone to intraplaque hemorrhage (IPH). These IPH are associated with
destabilization of the vulnerable plaques resulting in plaque erosion and plaque rupture resulting in
ACS. In atheroscleropathy the adventitial Vv invades the plaque in a malignant-like fashion and
concurrently is associated with chronic inflammation, as macrophages are being deposited within
the shoulder regions of these vulnerable plaques. These angiogenic Vv provide a custom delivery
vascular network for multiple detrimental substrates, which further accelerates the growth of these
vulnerable plaques and atheroscleropathy. There exists a vascularization paradox in MS and T2DM,
in that, angiogenesis within the plaque is induced and arteriogenesis is impaired.
Conclusion:  This review will attempt to provide a database of knowledge regarding the
vascularization process (angiogenesis and arteriogenesis) and its mechanisms to better understand
the increased cardiovascular risk and the increased morbidity and mortality associated with MS and
T2DM.
Historical background and introduction
Atheroma and atherosclerosis date to the times of the
ancient Egyptians (mummies had atherosclerosis and cal-
cification of coronary arteries). Fallopius (1575)
described a degeneration of the arteries into bone and at
this time the process was felt to be a natural result of the
aging process. Crell (1749) published a book regarding
hardening of the coronary arteries. He felt that the
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inflammation noted within plaques produced pus that
separated the muscular layer from the internal lining of
the diseased artery. He noted that when the pus hardened
it formed a scaly like change on the lining of these vessels.
At approximately this same time Boerhaave suggested that
hardening of the arterial wall occurred when the small
arteries that feed the muscular layer constricted and hard-
ened (ossified), which is the first description of the vasa
vasorum (the vessel within the vessel) directly involved in
the angiogenic process [1].
Morgagni (1761) noted tears in the soft portion of the
intimal surface of the walls of the aorta (the first descrip-
tion of plaque rupture) and made an important patholog-
ical and clinical observation. He noted the increased size
of the heart in patients with extensive ossifications and
that they had complained of chest pains while living.
Hodgson (1815) described the macrophage in atheroscle-
rotic lesions. He further described that the atherosclerotic
process occurred within the intima. The idea that athero-
sclerosis is a chronic inflammatory disease is not necessar-
ily new even though there is excitement today in the
current literature as we continue to better understand this
process [2,3].
Cruveihier (1833) referred to the atherosclerotic process
as an arteritis. He felt that blood clots formed to repair the
artery and that ossification of the vasa vasorum resulted in
bony plaques formed to prevent aneurysms. Rokitansky
(1841) is remembered for his thrombogenic theory. Vir-
chow (1856), considered by many to be the father of
pathology, was of the opinion that substances permeate
the wall of the arterial vessel wall (endarteritis deform-
ans). Vogel (1847) first identified cholesterol as being a
major component of the atherosclerotic plaques. As can
be seen the theories of atherosclerosis are legion and sev-
eral have prevailed throughout history. The thrombogenic
theory of Rokitansky, the inflammatory theory of Hodg-
son, Virchow and others, the insudation theory of Rossle
and Doerr, and the lipid theory of Vogel have persisted
throughout time. As can be seen in just this brief historical
outline, the atherosclerologists of today have a proud her-
itage upon which to build for the future [1]
In 1999 the late Jeffrey M. Isner (a leader in the field of
biorevascularization with phVEGF 165 gene transfer)
authored an editorial in the journal Circulation entitled:
Cancer and Atherosclerosis: The Broad Mandate of Angio-
genesis, which triggered this discussion of atheroma and
its malignant transformation [4].
The metabolic syndrome (MS), prediabetes (PD), and
overt type 2 diabetes mellitus (T2DM) are associated with
an accelerated atherosclerosis termed atheroscleropathy
(figures 1,2). This atheroscleropathy adds to the rapidity
of the malignant transformation due to multiple meta-
bolic toxicities, which are associated with multiple injuri-
ous stimuli to the endothelium with associated
endothelial dysfunction.
Angiogenesis induced
It is important to compare and contrast atheroma and
atherosclerosis as being a benign and malignant condi-
tion respectively: Atheroma implies a benign wound heal-
ing response to injury with resolution and fibrous change
rather than progression. In contrast: Atherosclerosis
implies a malignant transformation with chronic inflam-
mation, fibroproliferation and angiogenesis (table 1).
In 1971, Folkman introduced the hypothesis that tumors
were angiogenic dependent [5]. Since atheroma is a
benign healing process it is prudent to consider how it
transforms to become malignant and the number one
cause of death and disability.
The working definition of atherosclerosis:
Atherosclerosis is a systemic dysfunctional endothelial,
focal occurring, chronic inflammatory, fibro-prolifera-
The important role of the metabolic syndrome in the devel- opment of coronary heart disease Figure 1
The important role of the metabolic syndrome in the 
development of coronary heart disease. The metabolic 
syndrome consists of multiple clinical syndromes and meta-
bolic abnormalities, which accelerates the atherosclerotic 
process. The NCEP ATP III guidelines allows for an easier 
identifications of these patients at risk. While insulin resist-
ance is central to the development of coronary heart disease, 
it can be seen that each of the components now contained 
within the metabolic syndrome can individually contribute to 
CHD risk. Each of these factors is combined as in the meta-
bolic syndrome they become synergistic.
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tive, prothrombotic, angiogenic, multifactorial disease
of the arterial intima caused by the retention of modi-
fied low-density lipoproteins, hemodynamic, and
reductive-oxidative (redox) stress [6-10].
Atheroscleropathy = accelerated atherosclerosis in MS,
PD, and T2DM.
There is no question that atherosclerosis is a systemic dys-
functional endothelial disease. It is focal, in that, lesions
have a tendency to occur at predictable anatomic sites of
the arterial tree. It predictably occurs at bifurcations, side
branches, and opposite flow dividers at areas of low
endothelial shear stress and turbulent blood flow. There is
an orderly cephalad progression over time starting with
the iliacs and progressing cephalad to the aorta, coronar-
ies, carotids and cerebral vessels.
The PDAY (Pathobiological Determinants of Atheroscle-
rosis in Youth) study and the Korean autopsy study
revealed that the atheromatous process begins early in
youth and young adulthood [11,12]. By the fifth and sixth
decades the devastating clinical effects of this malicious
disease are witnessed and will increase as our population
The atheroscleropathy associated with MS, PD, and T2DM has many deleterious pathways Figure 2
The atheroscleropathy associated with MS, PD, and T2DM has many deleterious pathways. There are multiple 
deleterious pathways associated with MS, PD, and T2DM. Atheroscleropathy is pro oxidative-redox stress, prothrombotic, 
pro-fibrotic, and pro-inflammatory. Each of these mechanisms and the disease process of atheroscleropathy promote a pro-
angiogenic environment and associated with a diabetic vascularization paradox, in that, plaque angiogenesis is induced and arte-
riogenesis is impaired.
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ages (as the "baby boom" generation transitions to the
"senior boom" generation).
As the eccentric atheroma intima thickens, there is a rela-
tive ischemia of the vessel wall, which is a potent inducer
of the adventitial angiogenic vasa vasorum (Vv) [13]. The
chronic inflammation that runs concurrently serves to
magnify this angiogenesis to the point that it appears to be
uncontrolled as if a malignancy (table 1). The chronic
inflammation (with its associated tissue factor) along
with endothelial cell dysfunction contributes to the pro-
thrombotic state of the atherosclerotic plaque. The reten-
tion of modified low-density lipoproteins is felt to be a
key pathogenic event and possibly an absolute require-
ment for lesion development and progression [14,15].
The hemodynamic stress is a prerequisite, as atherosclero-
sis does not develop within the venous system due to a
low pressure – low shear stress environment. Also, pulmo-
nary arteries do not develop atherosclerosis unless pulmo-
nary hypertension is present [6-10].
There is an accelerated atherosclerosis (atheroscleropa-
thy) associated with metabolic syndrome (MS), prediabe-
tes (PD), and overt type 2 diabetes mellitus (T2DM).
Plaque angiogenesis and intraplaque hemorrhage may be
associated with unstable vulnerable plaques and contrib-
ute to plaque destabilization.
Currently the vulnerable plaque has been defined as con-
taining the following: 1. Large lipid core. 2. Thin fibrous
cap. 3. Inflammatory changes at the shoulder of the
fibrous cap. 4. Decreased smooth muscle cells within the
fibrous cap. [2,16] (figure 3)
An additional element within the vulnerable plaque
should be considered: Number 5.
5. Increased angiogenesis within the intima and media.
Adventitial derived Vv promoting plaque angiogenesis is
an important aspect of the vulnerable plaque. The impor-
tant association of plaque angiogenesis and inflammation
is rapidly emerging. Morphologically, the adventitia is the
Table 1: The role of angiogenesis in the classification of arterial lesions compared to tumors: benign verses malignant
ATHEROMA (Benign) ADENOMA (Benign)
Growth locally Growth locally
Types I and II: (Initial lesion – fatty streak) Lesion remains less 3–4 mm if no angiogenesis
Type III: (Isolated extracellular lipid pools) Preatheroma (Tissue damage 
and disorder) [Virmani R, Pathological intimal thickening]
Type IV: (Formation of lipid core) Atheroma (Massive structural damage 
to intima). ANGIOGENESIS INDUCED: [Virmani R, fibrous cap 
atheroma]
ANGIOGENESIS INDUCED:
Malignant Transformation ANGIOGENESIS Malignant Transformation ANGIOGENESIS
Type V: Fibroatheroma (SMC) Proliferation – Migration Fibromuscular 
tissue layers produced Thickening of intima and media ANGIOGENESIS 
Development of protective fibrous cap [Virmani R, thick-cap fibrous 
atheroma]
Now rapid cell growth
Exponential
More invasive displacing normal tissue
ANGIOGENESIS:
ANGIOGENESIS:
Type VI: Surface defect, hematoma, thrombosis [Vermani R, Thin-cap 
fibrous atheroma: Vulnerable Plaque]
ANGIOGENESIS MAGIFIED:
Intraplaque hemorrhage: (IPH):
Contributing to unstable vulnerable plaque rupture and thrombosis.
Cholesterol emboli to: Extremities (PAD), Kidney, Brain. (TIAs), 
Coronaries
Bleeding and ulceration
Metastasis to Liver, Lung Brain
Type VII: Calcification predominates. ANGIOGENESIS: Recapitulated in distant organs
Type VIII: Fibrous tissue changes predominate. Type V to type VIII: 
Recapitulation of lesions: Repeated layering of eccentric atheroma.
ANGIOGENESIS: Recapitulated in distant organs
DEFINITIONS TO FOLLOW:
1. ATHEROMA: G. athere, gruel or porridge + oma, tumor.
2. TUMOR: L. a swelling. Syn. neoplasm.
3. NEOPLASM: G. neos, new. plasma, thing formed.. Syn. New growth.
4. BENIGN: Fr. Fr.L., benignus, kind. Denoting the mild character of an illness or the non malignant character of a neoplasm.
5. MALIGNANT: L. maligno p.(ant). To do anything maliciously. Resistant to treatment; occurring in sever form, and frequently fatal; tending to 
become worse. In reference to neoplasm, having the property of being locally invasive and destructive with growth and metastasis.
6. ATHEROSCLEROSIS: G. athere, gruel or porridge + skleros, hard. (A malignant form of atheroma implying the presence of a 
proinflammatory, prothrombotic, profibrotic, pro oxidative – redox stress, and proangiogenic state).
SOURCE: Steadman's Medical Dictionary. 26th Edition. 1995 Williams and Wilkins. Baltimore, MD. USACardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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last new frontier involved in the development of vulnera-
ble plaques. Early on in the descriptions of atherosclerosis
the term arteritis was used to define this process and
pathologists pointed to the chronic (mononuclear –
monocytes, lymphocytes, and rare mast cells) inflamma-
tory reaction within the adventitia.
Barger's now classic work in 1984 entitled: "Hypothesis:
Vasa vasorum and neovascularization of human coronary
arteries" has made clinicians and researchers aware of the
importance of the Vv in nourishing the arterial vessel wall
in health and disease [17,18]. He was able to show with
the injection of white silicone polymer into the coronaries
of atherosclerotic vessels a "malignant like" infiltration of
microvessels into the media and intima of the
atherosclerotic diseased segments. He was able to show
that this neovascularization (angiogenesis) of the vessel
wall was originating from the adventitial vasa vasorum. In
the healthy segments of the same coronary artery there
was no involvement of angiogenesis (figure 4).
Later it was revealed that neovascularization could arise
from the lumen as well as the adventitial vasa vasorum.
Kumamoto et al. [19] a decade later in 1995 was able to
show in diseased atherosclerotic epicardial arteries that
intimal vessels originated 28 times more frequently from
the adventitial vasa vasorum than those originating from
the lumen. He was also able to reveal that intimal-medial
neovascularization was closely associated with the inflam-
matory reaction within the plaque, established early in the
atherosclerotic process, and capable of regression.
Most authors feel the intimal-medial neovascularization
arises more frequently from the adventitial vasa vasorum.
For the sake of this discussion and the vulnerability of the
atherosclerotic plaque it does not make a tremendous dif-
ference as both adventitial and luminal microvessels are
both very fragile and prone to leak and rupture creating
intraplaque hemorrhages (IPH). Barger also suggested
that with systolic surges of blood pressure these microves-
sels would be prone to rupture leading to IPH. These IPH
could certainly act as an injury or angiogenic stimulus for
Vulnerability of the thin cap fibroatheroma Figure 3
Vulnerability of the thin cap fibroatheroma. The vul-
nerable plaque: Currently the vulnerable plaque has been 
defined as containing the following: 1. Large lipid core. 2. 
Thin fibrous cap. 3. Inflammatory changes at the shoulder of 
the fibrous cap. 4. Decreased smooth muscle cells within the 
fibrous cap. This "Hot" – vulnerable thin-cap fibrous athero-
matous plaque is associated with angiogenesis, inflammation, 
being lipid laden and acidic, and fibrotic. The endothelium is 
activated and these plaques are prone to rupture resulting in 
acute coronary syndromes.
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Plaque angiogenesis induced in MS, PD, and T2DM Figure 4
Plaque angiogenesis induced in MS, PD, and T2DM. 
Angiogenesis within the unstable atherosclerotic plaque: In 
health the vasa vasorum usually has a single vessel that runs 
parallel to each side of the epicardial artery being nourished 
with occasional interconnecting conduits from one side of 
the artery to the other. In this image, the native parallel 
adventitial vasa vasorum (in black) can be differentiated from 
the red neovascularization of the intima and media. The 
unstable, vulnerable plaques are associated with a malignant 
like invasion of the intima-media by adventitial derived vasa 
vasorum fragile vessels, which are prone to rupture resulting 
in intraplaque hemorrhage. These intraplaque hemorrhages 
accelerate plaque vulnerability and are associated with plaque 
rupture and acute coronary events.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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the progression of increasing numbers of microvessels
within the atherosclerotic vessel wall. Vessel wall remode-
ling including angiogenesis is important in the
development of the vulnerable unstable atherosclerotic
plaque and an important factor in the development of
acute coronary syndromes (ACS).
Angiogenesis in the setting of the vulnerable plaque is a
double-edged sword. It is the body's natural protective
response to ischemic injury of the vessel wall providing
oxygen and metabolic nourishment as the intima
undergoes a positive outward remodeling and thickening,
while at the same time may contribute to plaque growth
through the response to injury mechanism to IPH (table
2) (figure 3). As the numbers of these "malignant like"
microvessels increase within the plaque, the numbers of
IPH increase as a result and contribute to the instability of
the atherosclerotic plaque.
Even though the IPH may be clinically silent, it may result
in:
1. Rapid plaque growth due to increase in the size of the
plaque, as well as, the necrotic lipid core.
2. Serve as an angiogenic stimulus, thus auto-amplifying
the continued vasa vasorum (angiogenic process) further
increasing the chance for IPH.
3. Serve as an antigenic stimulus, thus auto-amplifying the
continued intraplaque inflammatory response.
4. Activate the inflammatory macrophages at the shoul-
ders of the plaque causing them to secrete their matrix
metalloproteinases (MMPs) or collagenases causing a
weakening and thinning of the protective fibrous cap as
well as possible digestion of the fibrous cap resulting in
erosion, fissuring, rupture, with platelet adhesion,
aggregation, and ensuing thrombus formation with acute
coronary syndrome.
Since 2002 and during 2003 there has been an increasing
interest in the vasa vasorum and the adventitia regarding
plaque vulnerability and plaque rupture. Fuster V et al.
have done much to rejuvenate and expand Barger's origi-
nal exciting findings in 1984 [20].
A focus on plaque angiogenesis (vv) and the MS, PD, and 
T2DM
In 2003, Purushothaman KR et al. have presented data
that neovascularization is the most powerful independent
predictor for plaque rupture in vulnerable plaques (p=
0.0001) followed by disruption of the internal elastic lam-
ina (p= 0.01), and fibrous cap thinness (p= 0.02) [21].
This exciting publication has also prompted this current
review and has extended the important role of the
adventitia and plaque angiogenesis in our understanding
of remodeling of the arterial vessel wall in macrovascular
disease and the development of the vulnerable plaque in
MS, PD, and T2DM.
Just as atheroscleropathy has been used to describe the
accelerated atherosclerotic process, the term intimopathy
may be used to describe the accelerated positive outward
remodeling and neovascularization of the intima and
media in MS, PD, and T2DM. This neovascularization is
derived from the adventitial vasa vasorum (Vv) and may
also be termed intimal microangiopathy, which is similar
to the retinopathy found in the retinal vascular bed.
The Vv is called into the intima and media by a process of
angiogenesis, which is increased in MS, PD, and overt
T2DM. As can be seen from table 1 this occurs at an accel-
erated rate in stages IV and V (table 2). There are at least
Table 2: The 10-point process of Angiogenesis:
(See FIGURE 4)
1. Endothelial cell activation and Proliferation.
2. Local Vasodilatation.
3. Increased vascular permeability.
4. Accumulation of extravascular fibrin* PAI-1
5. Proteolytic degradation of basement membrane. MMP-9 MMP-2
6. Thin cytoplasmic processes are extended from the endothelial cell.
7. Directed migration into surrounding ECM toward the Angiogenic Stimulus (IPH or Ischemia).
8. E. Cells. elongate and align to form a capillary Sprout.
9. E. Cell. Division proximal to the migrating tip.
10. Reconstitution of the basement membrane.
• PAI-1 inhibits fibrinolysis.
• PAI-1 inhibits uPA and tPA and PLASMIN production:
• PAI-1 inhibits the conversion of latent MMPs to active MMPs
• THUS interfering with remodeling and arteriogenesisCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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three mechanisms driving the angiogenic response in
atheroscleropathy and intimopathy – intimal microangi-
opathy associated with MS, PD, and T2DM:
1. The initial angiogenic response by the adventitial Vv
(via angiogenesis) is stimulated by hypoxia and ischemia
as the intima and media undergoes thickening (exceeding
the ability of simple diffusion of nutrients from the lumen
[usually greater than 0.35 millimeters]) and positive out-
ward remodeling [13]. This hypoxia induces the adventi-
tial Vv to undergo angiogenesis due to Hif-1 and VEGF
stimulation [22].
2. In MS and T2DM there exists a microangiopathy within
the adventitial derived Vv microvessels. There is increased
vascular permeability (leaky micro-vessels) of red blood
cells (RBCs) and plasma proteins (comparable to the pro-
teinuria in diabetic nephropathy) into the interstitium of
the ECM due to the microangiopathy, which instigates an
inflammatory response of monocytes and macrophages
[6,7,23,24]. The inflammatory response is excessive in
MS, PD, and T2DM and is further increased by the inflam-
matory signals induced by the increase of RBC plasma
membrane extravasation. The inflammatory macrophages
are a source of VEGF and other positive regulators of
angiogenesis.
3. As the numbers of angiogenic vessels (Vv) increase, the
probability of intraplaque hemorrhage increases with
extravasated RBCs. The adventitial Vv microvessels within
the atherosclerotic plaque are very fragile and prone to
rupture as previously described. The inflammatory
infiltrate runs concurrently with the development of the
intimopathy (neovascularization) as oxidized LDL cho-
lesterol, glycated LDL-cholesterol, and glycoxidated LDL-
cholesterol (all of which are forms of modified LDL-cho-
lesterol) also induce an antigenic stimulus and calls in the
inflammatory macrophage, which is known to accumu-
late within the shoulder region of vulnerable atheroscle-
rotic plaques.
Kolodgie FD et al. have just published an important article
revealing the importance of the RBC plasma membranes
and their deposition within the vulnerable atherosclerotic
plaques [25]. The RBC plasma membrane deposition
within the necrotic core, in addition to, free cholesterol,
macrophage infiltration, and enlargement of the necrotic
core is currently felt to be an additional atherogenic
stimulus and concurrently increases the risk of plaque
destabilization and rupture with ensuing ACS. This new
information contributes to the importance of plaque
angiogenesis, IPH, and aid in the understanding of the
important role they play in the development of ACS.
Synengism between the inflammatory infiltrate and the 
vasa vasorum
The inflammatory infiltrates of the vulnerable shoulder
region are responsible for:
1. Recruitment of more monocytes (fueling the inflamma-
tory process).
2. Synthesis of tissue ACE and Tissue Factor (TF), which
are known to be direct positive regulators of angiogenesis.
3. Promoting a thinning of the fibrous cap. (IFN gamma
of the t-lymphocytes). [26]
4. Increasing the apoptosis of the smooth muscle cell
(SMC). (IFN gamma of the t-lymphocyte). [26]
5. Promoting the increased modification of LDL-choles-
terol.
6. Promoting the arrival of the t-lymphocyte to the shoul-
ders of the plaque.
7. TNF alpha, IL-1, and IFN gamma by the t-lymphocyte.
8. An increased synthesis of VEGF and FGF.
Summary: 1. Tissue Factor. 2. Tissue ACE. 3. MMPs. 4.
Cytokines and growth factors (figure 3) [6].
The fate of the smc and macrophage are opposed
It is interesting to note that while there is synergism
between the vasa vasorum and the inflammatory infiltrate
there exists an opposing phenomenon between the SMC
and the macrophage. The SMC is initially damaging (caus-
ing a progression of the atheroma and atherosclerotic
plaque through fibroproliferation) and later in the athero-
sclerotic process becomes protective providing the
strength of the fibrous cap [27]. The macrophage is ini-
tially protective (removing or modifying the injurious
stimuli i.e. modified LDL-cholesterol to promote healing)
and later becomes important in accelerating the disease
process (the inflammatory process) by promoting insta-
bility and plaque rupture.
Vasa vasorum: a custom delivery system
The vasa vasorum acts as a custom-delivery system for the
following substrates:
1. Substrates of the Renin Angiotensin Aldosterone
System.
2. Substrates of native LDL-cholesterol and modified LDL-
cholesterol.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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3. Substrates for angiogenesis. The endothelial progenitor
cells, as well as, the endothelial cell itself via migration
associated with the 10-point process of angiogenesis
(table 2) (figure 5).
4. Supply the route for the second wave of inflammatory
cells to the intima and vulnerable shoulder regions of the
plaque. Fueling the inflammatory process. The first wave
originating from the endothelial luminal surface.
5. Supply the direct route for the adventitial fibroblasts
and TGF-beta allowing for intimal plaque expansion.
During the past few years there have been important arti-
cles published concerning the importance of angiogenesis
within the unstable atherosclerotic plaque. Kwon
reported (with micro computer tomography in the coro-
nary porcine model) rapid, extensive development of vasa
vasorum angiogenesis in coronary vessels. These were
induced by a high fat diet in three months [28,29]. Burke
and Virmani revealed that plaque rupture in sudden death
is related to vasa vasorum angiogenesis in addition to the
chronic macrophage inflammatory response [30]. O'Brien
was able to show that adhesion molecules (VCAM, ICAM
and E-Selectin) expression was in the endothelial lining of
the angiogenic vasa vasorum [31]. Thus, later in the
atherosclerotic process the angiogenic vasa vasorum may
be more responsible for the delivery of the previously dis-
cussed harmful molecules and substrates than diffusion
through the traditional endothelial lumen surface early in
the atherosclerotic process.
Recently de Boer and van der Wal [32] substantiated the
above by staining for endothelial cells within the vulnera-
ble plaque and concluded that angiogenesis and expres-
sion of adhesion molecules by the vasa vasorum may
sustain the influx of inflammatory cells with subsequent
plaque destabilization. They as O'Brien found that E-
Selectin, ICAM and VCAM were up regulated. In addition
they found the expression of CD40 to be increased. This
custom delivery system of angiogenic vessels (Vv) acts to
deliver the harmful substrates directly to the vulnerable
plaque in addition to supplying a route for the chronic
inflammation.
This is quite reminiscent of the angiogenic vessels noted
in malignant tumors, which provides nourishment for the
exponential growth and a vascular route for the metastasis
of tumor cells to other organs.
In summary, atherosclerosis is malicious, resistant to
treatment, occurring in severe form, frequently fatal,
locally invasive, and destructive with growth, resulting in
chronic inflammation, fibroproliferation, and angiogen-
esis (table 1).
Biomechanical instability may be related to angiogenesis 
within the vulnerable plaque: "the slapped plaque effect"
Muller in 1994 [33] revealed to the atherosclerotic com-
munity that the malignant atheroma (vulnerable thin-cap
fibrous atheromatous plaque) had a tendency to rupture
with certain activities of daily living. He was able to relate
cardiovascular events to certain triggers:
SEASONAL: winter
TIME of DAY: mornings
DAY OF THE WEEK: Mondays
RELATED TO: exertion, anger, and fear (the fight or
flight syndrome).
Exertion, anger, and fear are all related to a surge in adren-
alin-epinephrine, norepinephrine. These vasoactive mole-
cules when excreted would have a tendency to concentrate
in areas where there are increased capillary densities such
The 10 point process of angiogenesis visulized Figure 5
The 10 point process of angiogenesis visulized. The 10 
point process of angiogenesis: Intraplaque hemorrhage (IPH) 
may serve as an angiogenic stimulus for the further develop-
ment of excessive vasa vasorum invasion of the intima and 
media, resulting in an even more unstable vulnerable plaque: 
prone to rupture. As the MMPs drill the openings for the 
invading adventitial Vv they may also contribute to the dis-
ruption of the internal elastic lamina, which contributes to 
the plaques instability. Additionally, the extravasated RBC 
plasma membranes become incorporated into the necrotic 
core and contribute to the enlargement of the necrotic core, 
as well as, providing an antigenic stimulus for the continued 
intraplaque inflammatory response.
12/20/03 108 Lumen
E.C.
Vasa
Vasorum
Intimal Space
Basement
Membrane
IPH
Angiogenic
Stimulus
Prolif.
Media
Prolif.
Adventitial
Vasa V
Internal Elastic Lamina
MMP-2 constitutive
MMP-9 Induced
Disruption of IELCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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as the vulnerable, angiogenic-laden plaques as compared
to the healthy segments of coronary arteries. Plaques have
tendency to develop in an eccentric fashion with frequent
layering of one active atheroma over another. The fixed
eccentric plaque with its increased angiogenesis cannot
constrict in response to this increased concentration of
vasoconstrictive molecules. The vasa vasorum does com-
municate to the opposing side of the eccentric plaque
demonstrated by Barger's work. The vasoactive molecules
could stimulate the smooth muscle cells within the
opposing healthy media opposite the fixed plaque and
result in a slapping of the fixed diseased vessel wall. This
would result in increased biomechanical stress to the
unstable, vulnerable, angiogenic laden, rupture prone
atherosclerotic plaque and contribute to IPH.
Recently, Stefanadis C [34] and Madjid M [35] have been
able to demonstrate that the vulnerable plaque has a
higher temperature than stable plaques with a tempera-
ture probe. The increased temperature of the probe was
associated with elevations in C-reactive protein (CRP),
serum amyloid A, and macrophage content. The authors
contend that they are measuring indirectly the activity of
plaque inflammation, when in fact; they may be measur-
ing the increased temperature as a result of the increased
angiogenic blood flow seen by the probe through a vul-
nerable and thinned fibrous cap.
To summarize, the constant injury and response to injury
to the arterial vessel wall causes this natural repair and
healing process (remodeling) to go awry with plaque ang-
iogenesis and a malignant transformation (table 1).
Shared simularities in vascular beds: diabetic intimopathy 
and retinopathy
The term intimopathy is used to describe the remodeling
within the arterial vessel wall and includes ECM expan-
sion and neovascularization of the adventitial vasa
vasorum. This intimopathy is comparable to the ang-
iogenic neovascularization seen in diabetic retinopathy
and carries a similar risk when discussing IPH and retinal
hemorrhage, each having a detrimental outcome. In the
case of retinopathy and retinal hemorrhages there is
reduced vision and blindness, whereas in intimopathy
there is IPH, destabilization of the vulnerable atheroscle-
rotic plaque, and plaque rupture with ACS and excessive
remodeling of the involved plaque [10].
Arteriogenesis impaired
MS, PD, and T2DM are associated with impaired coronary
collateral vessel formation via the process of arteriogen-
esis [10,36].
The formation of coronary collateral vessels (arteriogen-
esis) is a compensatory mechanism secondary to
repetitive or chronic epicardial arterial blockage by arterial
vasospasm or thrombosis. The process of arteriogenesis
(collateral vessel formation) begins with small (20
micron diameter vessels) preexisting, quiescent, mini-
mally – functioning arterioles and remodels them into
larger (1–2 millimeter diameter vessels) more functional
arterioles capable of carrying more oxygen enriched blood
to ischemic tissue (a mini auto-coronary artery bypass).
The shear stress associated with a pressure gradient as a
result of epicardial coronary vasospasm or thrombosis is
responsible for inducing the arteriolar remodeling proc-
ess. In contrast, angiogenesis begins with capillaries and
ends with more capillaries (figure 6,7). Important in this
remodeling process are the shared cytokines, chemokines,
growth factors, the inflammatory monocyte, and the
extracellular matrix metalloproteases (MMPs) (table 4)
[10].
Recently Waltenberger J et al. were able to delineate the
importance of the monocyte. They were able to demon-
strate that monocyte migration was impaired in diabetes
and associated with impaired collateral formation
[37,38]. Panutsopulos D et al. were also able to
demonstrate an impairment of monocyte migration with
an associated increase in basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF)
mRNA [39]. While the monocyte is an important cell
associated with arteriogenesis and its impairment in
The spirit of vascularization Figure 6
The spirit of vascularization. This figure compares and 
contrasts the involved mechanisms of angiogenesis and arte-
riogenesis. S = substrates, P = promotors, I = inducers, R = 
results, I = the common role of inflammation, and T = time. 
This acronym helps to understand why angiogenesis is 
induced and arteriogenesis is impaired.
1/2/04 112
Angiogenesis
Substrate:  Preexisting capillaries
Promotors:  Hif-1 TACGTGCT
Inducers:  Ischemia
Result:  Increased Capillary
density
I N  F L A M M  A T  I  O  N Intraplaque
Time :   Days. Macrophages
FGF-1 FGF-2  Ox-LDL induced
VEGF PDGF VEGF.
MCP-1 , GM-CSF
Substrate:  Preexisting Arterioles
Promotors: Shear stress responsive
element GAGACC
Inducers:  Shear stress INFLAM
Result:  New Arteries.
I N  F L  A  M  M  A T  I O  N Circulating Cells
Time:  Days to WEEKS/ Mo.  Monocytes
Remodeling Arteriogenesis
THE“SPIRIT”     OF       VASCULARIZATION
GOOD !
WITHIN
PLAQUE
BAD !
IPH
OUTSIDE
PLAQUE
GOOD!
(HIBERNATING
MYOCARDIUM)
News in Physiological Sci.
June 1999; 14: 121-125
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migration will have a detrimental effect on remodeling
collateralization there may also be a defect associated with
MS, PD, and T2DM affecting the remodeling of the extra-
cellular matrix (ECM).
MS, PD, and T2DM are associated with increased PAI-1 [8-
10]. PAI-1 inhibits both tissue and urokinase plasmino-
gen activator resulting in impaired synthesis of plasmin.
Plasmin is known to be very important in activating latent
MMPs to active MMPs [40]. Therefore, PAI-1 excess may
additionally serve to impair monocyte migration in addi-
tion to inhibiting the ECM remodeling collateralization
(intima – media) of preexisting arterioles to the newly
remodeled collateral arterioles (figure 7) [10].
There is a diabetes vascularization paradox in that angio-
genesis is induced and arteriogenesis is impaired.
The diabetes vascularization paradox: accelerated 
intraplaque angiogenesis and impaired arteriogenesis
Angiogenesis and arteriogenesis are two distinct forms of
postnatal vasculogenesis. Angiogenesis is induced by
ischemia through the promoter Hif-1 TACGTGCT pro-
moter and VEGF activity, whereas arteriogenesis is
Impairment of remodeling collateralization due to PAI-1 Figure 7
Impairment of remodeling collateralization due to PAI-1. PAI-1 elevations impair fibrinolysis and contribute to a pro-
thrombotic state in MS, PD, and T2DM. Additionally PAI-1 elevations impair Arteriogenesis. Remodeling collateralization is 
impaired in MS, PD, and T2DM due to elevations in PAI-1. Conversion of plasminogen to plasmin by tPA – uPA is negatively 
effected by elevations in PAI-1. This defect in the generation of Plasmin results in decreased conversion of latent MMPs to 
active MMPs and impair the remodeling necessary for the required remodeling of the preexisting arterioles to larger arterioles 
necessary for a more functional blood flow around obstructed epicardial coronary arteries and obstructed peripheral vascular 
systems in MS, PD, and T2DM.
12/20/03 112
*Arteriole
*Newly Remodeled
Arteriole
^ MMP
^ tPA
^ ECM
Decreased
TIMP
ARTERIOGENESIS IMPAIRED BY DM.
“REMODELING COLLATERALIZATION”
IMPAIRED             BY DM.   DUE TO
^ PAI-1
FIBRIN
Tyagi SC,
Parker JL 
Temporal expression of extracellular
MMPs and tPA in the development of
collateral vessels in the canine model of 
coronary occlusion. Can. J. Physiol.
Pharmacol. 1996; 74: 983-995.
20 micron 1-2 mm
Pressure
Gradient
from
unoccluded
to occluded
arterial
vessel.
Plasminogen
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Table 3: Multiple metabolic toxicities in ms and t2dm: the a-flight acronym
Initiator Metabolic Defect Metabolic mediator Functional mediator Consequence ROS
AA M Y L I N
(Co-secreted – Co-packaged 
within the insulin secretory 
granule) by the islet Beta cell.
Insulin's "Fraternal Twin" 
Elevated in MS, PD, and Early 
T2DM)
Hyperamylinemia Activation of ANG II PKC Signal Transduction
Islet Amyloid IAPP Islet 
aggregation and deposition. 
Beta cell apoptosis – Beta cell 
defect.
ROS
IAPP Amyloid in islets 
contributing to Beta Cell 
defect. Possible deposition in 
the intima, mesangium, 
neuronal unit, and myocardial. 
REMODELING
ANG II
Via RAAS activation
In MS, PD, and T2DM
Ang II Excess Ang II Excess
Most potent stimulus for:
Activation of Vascular 
membrane bound NAD(P)H 
Oxidase Enzyme
PKC Signal Transduction. 
Superoxide production. 
Uncoupling of the eNOS 
reaction. TGF beta-1 
activation
ROS NAD(P)H oxidase 
Derived Superoxide
Myocardial, Renal, Intimal, 
Retinal, and Neuronal 
remodeling
AGE Advanced Glycation 
Endproducts
AFE Advanced fructosylation 
endproducts
AGE / AFE See Glucotoxicity 
(G)
RAGE activation
Receptor for AGE
Protein Cross – linking / 
Dysfunction
RAGE
Receptor for AGE
Matrix Defects Signal 
Transduction
Matrix Defects Signal 
Transduction
ROS Myocardial, Renal, 
Intimal, Retinal, Neuronal– 
Endoneurial Fibrosis
Advanced Lipoxidation 
Endproducts (ALE)
ALE Protein Cross – linking Matrix Defects Signal 
Transduction
ROS Matrix Remodeling
Antioxidant Enzymes: 
Antioxidant reserve 
compromised
Reduced – Dysfunctional 
eNOS, SOD, GPx, GSH, 
Catalase, and Vit. C.
Decreased NO Decreased NO REDOX 
STRESS
ROS REDOX STRESS
Antioxidant Enzymes: 
Absence of antioxidant 
network
IMPAIRED eNOS L-arginine 
BH4
Decreased NO Decreased NO ROS Decreased NO
AGING: Accumulation of 
multiple metabolic 
toxicities → ROS
Increased Ox-LDL-C, 
TNFalpha, Capase 3, 
Glomerulosclerosis.
Decreased NO: Decreased NO ROS Inflammation, Apoptosis
Atherosclerotic 
Nephropathy
ROS beget ROS
Atheroscleropathy
Decreased NO Self 
perpetuating
Decreased NO
Decreased NO Athero – 
emboli Activated Platelets See 
Thrombotic Tox.
ROS beget ROS Decreased 
NO
F Free fatty acid toxicity Elevated FFA LC acyl -CoA's Mitochondrial Defects ROS Cytotoxicity
L Lipotoxicity
Lipid Triad
FFA
ALE
Long chain acyl-COA's
Increased VLDL – VLDL 
Triglycerides and Small dense 
atherogenic LDL-Cholesterol 
with Decreased HDL-
Cholesterol LIPID TRIAD
LC acyl -CoA's Fat 
Accumulation
Non Adipose Accumulation 
of Fat (LC acyl -CoA's) in 
Adipose and Non Adipose 
Tissue
ROS Accumulation of fat in 
non adipose tissues resulting 
in Ceramide induced: 
Cytotoxicity
I Insulin toxicity
ENDOGENOUS
Insulin Resistance
Hyperinsulinemia
Hyperamylinemia in:
MS, PD, EARLY T2DM
Glut 4 is NO dependent 
Redox sensitive pathway
Ang II
Increase # AT-1 receptors
Cross-talk with AT-1
Increase FFA
Increase PAI-1
Increase Sympathetic tone 
and activity
Increased Na+ and H2O 
reabsorption
Increase Volume and Blood 
Pressure
Hypertension
HypeR
NAD(P)H
REDOX STRESS
SIGNAL PATHWAYS
PI3 Kinase / Akt (Protein 
kinase B) → MAP Kinase 
Shunt
ROS
ROS
ROS Extracellular Matrix 
Remodeling Islet, intimal, 
renal, myocardial, and 
neuronal.
Inflammation toxicity. 
"Inflammatory Cycle"
Activation of the innate 
immune system: IL-6, IL-8, 
TNF alpha
Macrophage (MPO) → 
Hypochlorous Acid 
Superoxide O2
•
Acute Phase Reactants: C-
Reactive Protein Serum 
Amyloid A Fibrinogen
NF kappa B Cellular Adhesion 
Molecules: ICAM, VCAM, and 
MCP-1
ROS Inflammation begets 
Inflammation " 
INFLAMMATORY CYCLE " 
ROS beget ROS
Insulin deficiency OVERT T2DM GLUCOTOXICITY 
POLYOL SORBITOL 
PATHWAY
REDUCTIVE STRESS 
NADH > NAD+ 
PSEUDOHYPOXIA
ROS
G Glucotoxicity Glycation / AGE See above See above See above
Protein inactivation Receptor-ligand defects Dysfunctional Signal 
Transduction
NO quenching Vasoconstriction Ischemia/Hypoxia ROSCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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induced by the shear stress promotor by the shear stress
responsive element (SSRE): GAGACC (figure 6) [41].
The atherosclerotic plaque angiogenic adventitial Vv
within atheroscleropathy is excessive and associated with
MS, PD, and overt T2DM. The Vv are induced by ischemia
as the intima-media undergoes positive outward remode-
ling. Additionally, the Vv angiogenesis is further induced
by the inflammatory process within the shoulder region
of the plaque, which is associated with the known ang-
iogenic factors: Tissue ACE, tissue factor, cytokines and
growth factors (TNF alpha, VEGF, FGF). MS, PD, and
T2DM are associated with multiple metabolic toxicities,
which are responsible for reactive oxygen species (ROS)
production (table 3). This elevated tension of redox stress
contributes to the ischemia within the plaque and induces
even more angiogenesis within the plaque.
In contrast arteriogenesis is induced and promoted by
shear stress in normoxic conditions (table 4). Redox stress
and ROS are elevated in the preexisting (un-remodeled)
arteriolar endothelial milieu in MS, PD, and T2DM and is
associated with endothelial dysfunction with decreased
eNOS activity and decreased generation of eNO. This
could result in an impaired initial vasodilatation and per-
meability ordinarily induced by increased shear stress in
the arteriogenic process. Terjung RL et al. and Matsunaga
T et al. have reported that arteriogenesis is eNOS and eNO
dependent [42,43]. Thus, the impairment in eNOS and
eNO (due to redox stress and ROS) [8] could impair the
initiation and progression of arteriogenesis and result in a
negative effect on remodeling collateralization.
Given that collateral formation is inhibited by NOS inhi-
bition, dysfunction or knockout, one can hypothesize that
eNOS dysfunction and – or decreased eNO may decrease
arteriogenesis through the following mechanism: a
decrease in arteriolar vasodilation would impair the nor-
mal arteriolar vasodilation due to eNOS and eNO and
decrease the pressure gradient between normal and
ischemic tissue. This would impair the normal increased
flow and the shear stress responsive element in the
collateral vessel undergoing remodeling collateralization,
as well as, decreasing endothelial cell permeability [44].
Future work is needed to establish if reversing endothelial
dysfunction associated with MS, PD, and T2DM could
restore improved arteriogenesis [10]. Thus it appears that
a blunted endothelial NO production as noted in MS, PD,
and overt T2DM could temper vascular remodeling and
arteriogenesis [45].
Excess in redox stress or ROS and PAI-1 elevation could
have an overall negative effect on arteriogenesis in MS,
PD, and overt T2DM (table 4).
Another possibility is the existence of early advanced gly-
cation end products (AGE) and that these AGE would
contribute not only to the impaired remodeling
collateralization phase but also contribute to additional
collagen cross linking within the extracellular matrix. If
glucotoxicity were to be better controlled this might
improve the remodeling phase of arteriogenesis in T2DM
by improving redox stress, endothelial dysfunction,
monocyte migration, and PAI-1 levels.
Endotheliopathy
MS, PD, and T2DM are associated with a diffuse endothe-
liopathy. This endothelial dysfunction can be related to
the three vulnerable arms of the endothelial nitric oxide
synthase (eNOS) reaction.
Macrophage Activation Increased Cytokines, TGF-
Beta
Cytotoxicity ROS
Free Radical Formation REDOX STRESS Cytotoxicity ROS
Auto-oxidation Free Radical Formation REDOX STRESS Cytotoxicity ROS
ORIGIN OF REDUCTIVE 
STRESS ! REDUCTIVE 
STRESS !
Polyol Sorbitol Pathway (eNO 
inhibits Aldose Reductase)
Increased NADH Lactate 
REDUCTIVE STRESS
REDOX STRESS Decreased 
NO Pseudohypoxia
Cytotoxicity ROS Ischemia/ 
Hypoxia
Decreased Taurine REDOX STRESS ROS Cytotoxicity
Increased DAG Increased PKC Signal Transduction REDOX 
STRESS
Ischemia ROS
Glucotoxicity Glucotoxicity Polyol – Sorbitol Pathway PAS + material Interstitium, 
Basement Membrane
Remodeling – CHF Diastolic 
Dysfunction
H Hypertension Toxicity
Homocysteine Toxicity
RAAS activation 
Hyperhomocysteinemia NO 
quenching and NEW: PPAR 
interaction.
Ang II Decreased GPx, 
DDAH with resultant ^ 
ADMA
NAD(P)H REDOX STRESS ^ 
ROS, O2', ONOO', 
nitrotyrosine
ROS Decreased NO, 
Endothelial Cell toxicity, 
dysfunction, and apoptosis
T Triglyceride Toxicity 
Thrombotic Toxicity Taurine 
(antioxidant) depletion
Triglyceride – FFA exchange See FFA – Lipotoxicity above 
eNOS uncoupling
REDOX STRESS Activated 
Platelets PAI-1 elevation 
Fibrinogen elevated. 
Decreased NO
ROS Athero-emboli ROS
Table 3: Multiple metabolic toxicities in ms and t2dm: the a-flight acronym (Continued)Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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Oxidative – redox stress is elevated in MS, PD, and T2DM
and results in the production of reactive oxygen species
(ROS). The multiple metabolic toxicities of the A-FLIGHT
acronym result in an abundance of ROS. These ROS inter-
Table 4: THE SPIRIT OF VASCULARIZATION (SEE FIGURE 6)
Process Plaque Angiogenesis: Induced Arteriogenesis: Impaired
Substrate S Capillary Arterioles
Promoter P Hif-1 TACGTGCT and VEGF Shear Stress SSRE: GAGACC
Inducer I Ischemia Shear Stress
Result R More Capillaries Larger remodeled Arteriole
Inflammation I (+) increases (+) increases
Time T Hours → Days Days → Weeks → Months
PAI-1 Increased in Diabetes (0) neutral Neutral effect: In Plaque. Ischemia 
"Shoulder" Macrophage and Hif-1 → VEGF override. 
Net effect neutral Plaque Angiogenesis remains 
induced: See Promoter and Inducer above.
(-) IMPAIRS Impairs Remodeling Collateralization 
due to negative effects on MMP activation and 
impaired ECM clearance for the remodeling 
collateralization mechanism.
ROS Increased in Diabetes (+) increases SYNERGISTIC (to the above) 
SPIRIT of vascularization
(-) IMPAIRS ? Neutral to Negative in Collateral 
Vessels: See Promoter and Inducer above. Shear 
Stress → eNOS upregulation and eNO may override 
the negative effect of redox stress.
In the eNOS knockout model: Collateral formation 
was not impaired and the decreased flow could be 
restored with exogenous NO. This area of study 
needs further evaluation.
Oxygen Content HYPOXIA NORMOXIA
Table 5: THE RAAS ACRONYM: GLOBAL RISK REDUCTION
R Reductase inhibitors (HMG-CoA). Decreasing modified LDL-cholesterol, i.e. oxidized, acetylated LDL-cholesterol. Decreasing 
triglycerides and increasing HDL-cholesterol Improving endothelial cell dysfunction. Restoring the abnormal Lipoprotein fractions. 
Thus, decreasing the redox and oxidative stress to the arterial vessel wall and myocardium.
Redox stress reduction.
A AngII inhibition or blockade:
ACE inhibitors – Angiotensin II receptor blockers: Both inhibiting the effect of angiotensin-II locally as well as systemically. 
Affecting hemodynamic stress through their antihypertensive effect as well as the deleterious effects of angiotensin II on cells at the 
local level – injurious stimuli-decreasing the stimulus for O2
•production. Decreasing the A-FLIGHT toxicities. Plus the direct-
indirect antioxidant effect within the arterial vessel wall and capillary. Antioxidant effects.
Aspirin antiplatelet, anti-inflammatory effect.
Adrenergic (non-selective blockade) in addition to its blockade of Prorenin → Renin
Amlodipine with its calcium channel blocking antihypertensive effect, in addition to its direct antioxidant effects.
Redox stress reduction.
AA g g r e s s i v e   control of diabetes to HbA1c of less than 7. (This usually requires combination therapy with the use of: Insulin 
secretagogues, insulin sensitizers (thiazolidinediones), biguanides, alpha-glucosidase inhibitors, and ultimately exogenous insulin.).
Decreasing modified LDL cholesterol, i.e. glycated – glycoxidated LDL cholesterol. Improving endothelial cell dysfunction. Also 
decreasing glucotoxicity and the oxidative – redox stress to the intima and pancreatic islet.
Aggressive control of blood pressure, which usually requires combination therapy, including thiazide diuretics to attain JNC 7 
guidelines.
Aggressive control of Hcy with folic acid and its associated pleiotropic positive effect on re-coupling the eNOS reaction by 
restoring the activity of the BH4 cofactor to run the eNOS reaction and once again produce eNO, as well as, its direct antioxidant 
effects: BH4 and eNOS stabilization
Redox stress reduction.
SS t a t i n s . Improving plaque stability (pleiotropic effects) independent of cholesterol lowering. Improving endothelial cell dysfunction. 
Plus, the direct – indirect antioxidant anti-inflammatory effects [45] within the islet and the arterial vessel wall promoting stabilization 
of the unstable, vulnerable islet and the arterial vessel wall. Style: Lifestyle modification: lose weight, exercise, and change eating 
habits. Stop Smoking
Redox stress reduction
() 1  L-arginine
O2
NAD(P)H NAD(P)H Oxidase
(2) eNOS
(3) BH4 →   + + + NO L-citrulline NAD(P)Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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fere with the eNOS reaction resulting in a decrease in
endothelial nitric oxide (eNO). The process of uncoupling
of the eNOS reaction allows this reaction to proceed with
the endothelium becoming a net producer of superoxide
[O2
•] instead of the quintessential, protective, anti-
inflammatory, antioxidant eNO. When L-arginine uncou-
ples from the eNOS enzyme via an intact necessary cofac-
tor tetrahydrobiopterin (BH4) the following reaction
ensues:
The BH4 requisite cofactor itself is quite sensitive to oxida-
tive – redox stress and can be oxidized to BH2 and BH3,
which will not run the eNOS reaction and allow uncou-
pling. This allows the endothelium to become a net pro-
ducer of superoxide instead of eNO. As can be seen it is
Abbreviations Table 3: In order of appearance.
Ang II Angiotensin II.
RAAS Renin angiotensin aldosterone system.
ROS Reactive Oxygen Species (O2
•, -OH•, H2O2, 1O2).
AT-1 Angiotensin type one receptor.
PKC Protein Kinase C.
IAPP Islet Amyloid Polypeptide.
TGFbeta-1 Transforming Growth Factor beta-1.
NAD(P)H oxidase Nicotine Adenine Di nucleotide Phosphate reduced oxidase.
AGE Advanced Glycation Endproducts.
AFE Advanced Fructosylation Endproducts.
RAGE Receptor for Advanced Glycosylation Endproducts.
ALE Advanced Lipoxidation Endproducts.
eNOS Endothelial Nitric Oxide Synthase.
NO Nitric Oxide.
BH4 Tetra Hydro Biopterin.
FFA Free Fatty Acids.
LC acyl -CoA's Long chain Acyl Co enzyme CoA.
VLDL Very low density lipoprotein.
LDL Low density lipoprotein.
HDL High density lipoprotein.
MS Metabolic Syndrome.
PD Prediabetes.
T2DM Type 2 Diabetes Mellitus.
PAI-1 Plasminogen Activator Inhibitor-1.
H2O Water.
Glut-4 Glucose Transporter-4.
PI3 Kinase Phosotidyl inositol 3 Kinase.
Akt Protein kinase B.
MAP Kinase Mitogen Activated Protein Kinase.
MAP Kinase Shunt MAP Kinase Shunt: The shunting away from the positive Glut 4 PI3 Kinase Akt pathway to the deleterious MAP 
Kinase pathway promoting remodeling due to an alteration in the NO redox sensitive PI3 Kinase /Akt pathway.
___
IL-6 IL-8 Interleukin-6 Interleukin-8.
TNF alpha Tumor Necrosis Factor alpha.
MPO Myeloperoxidase: Generation of Superoxide (O2
•) via hypochlorous acid HClO-
NF kappa B Nuclear Factor kappa B.
ICAM Inter Cellular Adhesion Molecule.
VCAM, Vascular Cellular Adhesion Molecule.
MCP-1 Monocyte Chemoattractant Protein-1
NADH Nicotinamide Adenine Dinucleotide reduced
NAD+ Nicotinamide Adenine Dinucleotide oxidized
DAG Diacylglycerol.
GPx Glutathione Peroxidase.
DDAH Dimethylarginine dimethylaminohydrolase.
ADMA Asymmetrical dimethyl arginine.
O2
• - ONOO• Superoxide – Peroxynitrite.
NAD(P)H NAD(P)  O2
O2
NAD(P)H Oxidase →  + + ′Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/1
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very important to have an adequate substrate, a proper
functioning eNOS enzyme, and the necessary cofactor
BH4. Folic acid is not only a methyl donor and aids in the
control of elevated homocysteine but also an electron and
hydrogen donor, which brings BH2 and BH3 back to the
requisite completely reduced BH4. These findings would
lead one to not only control the multiple metabolic toxic-
ities (A-FLIGHT table 3) but also provide folic acid in
adequate amounts to allow BH4 to run the eNOS reaction
fully re-coupled to once again become a net producer of
eNO [8,9].
Conclusion
MS, PD, and T2DM are associated with endothelial dys-
function and carry an elevated risk for both micro and
macrovascular disease that are often present at the time of
diagnosis of overt T2DM. Postnatal vascularization in a
response to injury mechanism to the endothelium and the
arterial vessel wall as well as the capillary bed result in
most of the complications associated with these disorders.
This review has focused on the arterial vessel wall in order
to better understand the development and acceleration of
macrovascular disease termed: atheroscleropathy and the
capillary bed in microvascular disease. The diabetic
vascularization paradox has been presented in order to
better understand the mechanisms involved in the finding
of angiogenesis being induced and arteriogenesis
impaired.
The important role of plaque angiogenesis and subse-
quent plaque destabilization has been presented as this
mechanism plays such an important role in plaque rup-
ture and acute coronary syndromes. The epicardial coro-
nary vessels and the peripheral arterial vessels are
involved with ischemic manifestations as a result of
atheroscleropathy and impaired arteriogenesis – collateral
vascular formation.
When you stand back and examine the overall vascular
health in MS, PD, and T2DM it becomes obvious that
treatment to prevent, slow, or halt these vascular abnor-
malities requires a global risk reduction approach in treat-
ment in order to treat the multiple metabolic toxic
abnormalities associated with this complex disease (figure
2) (table 3). We currently have multiple treatment regi-
mens available to use as each metabolic abnormality is
addressed clinically. The RAAS acronym is provided as a
tool to assist the clinician in the treatment of these com-
plicated multiple metabolic derangements (table 5). Each
therapeutic component of the RAAS acronym will have a
positive effect on the excessive angiogenesis and the
impaired arteriogenesis associated with MS and T2DM
atheroscleropathy [46-48].
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